Skip to main content
. Author manuscript; available in PMC: 2019 Jun 10.
Published in final edited form as: Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04

Table 1.

List of oncolytic adenoviruses in clinical testing

Oncolytic adenovirus Serotype Clinical phase Indication(s) NCI website
CG0070 5 I/II Bladder https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oncolytic-adenovirus-encoding-gm-csf
DNX-2401 (Tasadenoturev) 5 I & II Brain https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oncolytic-adenovirus-ad5-dnx-2401
LOAd703 5/35 I/II Pancreatic, ovarian, biliary, colorectal https://clinicaltrials.gov/ct2/show/NCT02705196
Telomelysin 5 I/II & II HCC melanoma https://www.cancer.gov/publications/dictionaries/cancer-drug/def/telomerase-specific-type-5-adenovirus-obp-301
ColoAd1 (Enadenotucirev) 3/11p I & I/II Solid tumors https://www.cancer.gov/publications/dictionaries/cancer-drug/def/enadenotucirev
ONCOS-102 5/3 I & I/II Solid tumors https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gm-csf-encoding-oncolytic-adenovirus-cgtg-102
VCN-01 5 I Pancreatic https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ph20-hyaluronidase-expressing-adenovirus-vcn-01

HCC, hepatocellular carcinoma; NCI, National Cancer Institute.